The antiatherogenic potential of oat phenolic compounds

Atherosclerosis

Volumn 175, Issue 1, 2004, Pages 39-49

  Liu, Liping ^a   Zubik, Ligia ^a   Collins, F William ^b   Marko, Melissa ^a   Meydani, Mohsen ^a  

^a TUFTS UNIVERSITY   (United States)

^b AGRICULTURE AND AGRI FOOD CANADA   (Canada)

Author keywords

Adhesion molecules; Antioxidants; Avenanthramides; Endothelial cells; IL 6; IL 8; MCP 1; Oats

Indexed keywords

ALPHA TOCOPHEROL; AMIDE; ANTIOXIDANT; AVENTHRAMIDE; CHEMOKINE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PHENOL DERIVATIVE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATHEROGENESIS; CELL ADHESION; CELL CULTURE; COLUMN CHROMATOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DRUG PURIFICATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MONOCYTE; MONOLAYER CULTURE; OAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICITY TESTING;

ANTIOXIDANTS; ARTERIOSCLEROSIS; AVENA SATIVA; BENZOIC ACIDS; CELL ADHESION; CELL ADHESION MOLECULES; CELL LINE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION MEDIATORS; MONOCYTES; PHENOLS; PLANT EXTRACTS; VITAMIN E;

EID: 2942518278     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.01.044     Document Type: Article

References (68)

1. Meydani M. Nutrition, immune cells, and atherosclerosis. Nutr. Rev. 56:1998;S177-S182
2. Stemme S., Hansson G.K. Immune mechanisms in atherogenesis. Ann. Med. 26:1994;141-146
3. Dustin M.L., Rothlein R., Bhan A.K., Dinarello C.A., Springer T.A. Induction by IL-1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 137:1986;245-254
4. Collins T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab. Invest. 68:1993;499-508
5. Strieter R.M., Koch A.E., Antony V.B., et al. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractantprotein-1. J. Lab. Clin. Med. 123:1994;183-197
6. Cybulsky M.I., Gimbrone M.A. Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251:1991;788-791
7. Li H., Cybulsky M.I., Gimbrone M.A. Jr., Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler. Thromb. 13:1993;197-204
8. Reape T.J., Groot P.H. Chemokines and atherosclerosis. Atherosclerosis. 147:1999;213-225
9. Xu L., Kelvin D.J., Ye G.Q., et al. Modulation of IL-8 receptor expression on purified human T lymphocytes is associated with changed chemotactic responses to IL-8a. J. Leuk. Biol. 57:1995;335-342
10. Yue T.L., Wang X., Sung C.P., et al. Interleukin-8: a mitogen and chemoattractant for vascular smooth muscle cells. Circ. Res. 75:1994;1-7
11. Koch A.E., Polverini P.J., Kunkel S.L., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 258:1992;1798-1801
12. Luster A.D. Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:1998;436-445
13. Graves D.T., Jiang Y. Chemokines, a family of chemotactic cytokines. Crit. Rev. Oral Biol. Med. 6:1995;109-118
14. Onozaki K., Akiyama Y., Okano A., et al. Synergistic regulatory effects of interleukin-6 and interleukin-1 on the growth and differentiation of human and mouse myeloid leukemic cell lines. Cancer Res. 49:1989;3602-3607
15. Ikeda U., Ikeda M., Oohara T., et al. Interleukin stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am. J. Physiol. 260:1991;H1713-H1717
16. Loppnow H., Libby P. Proliferating or interleukin-1-activated human vascular smooth muscle cells secrete copious interleukin-6. J. Clin. Invest. 85:1990;731-738
17. Wu D., Koga T., Martin K.R., Meydani M. Effect of Vitamin E on human aortic endothelial cell production of chemokines and adhesion to monocytes. Atherosclerosis. 147:1999;297-307
18. Martin K.R., Wu D., Meydani M. The effect of carotenoids on the expression of cell surface adhesion molecules and binding of monocytes to human aortic endothelial cells. Atherosclerosis. 150:2000;265-274
19. Devaraj S., Li D., Jialal I. The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin-1-beta secretion, and monocyte adhesion to endothelium. J. Clin. Invest. 98:1996;756-763
20. Koga T., Meydani M. Effect of plasma metabolites of (+)-catechin and quercetin on monocyte adhesion to human aortic endothelial cells. Am. J. Clin. Nutr. 73:2001;941-948
21. Anderson J.W. Dietary fibre % complex carbohydrate and coronary artery disease. Can. J. Cardiol. 11(Suppl G):1995;55G-62G
22. Katz D.L., Nawaz H., Boukhalil J., et al. Effects of oat and wheat cereals on endothelial responses. Prev. Med. 33:2001;476-484
23. Collins FW. Oat phenolics: structure, occurence and function. In: Webster FH, editor. Oats: chemistry and technology. St. Paul, MN: American Association of Cereal Chemists; 1986. p. 227-95.
24. Collins F.W. Oatphenolics: avenanthramides, novel substituted N-cinnamoylanthranilate alkaloids from oat groats and hulls. J. Agric. Food Chem. 37:1989;60-66
25. Collins F.W., McLachlan D.C., Blackwell B.A. Oat phenolics: avenalumic acids, a new group of bound phenolics acids from oat groats and hulls. Cereal Chem. 68:1991;184-189
26. Collins F.W., Mullin W.J. High-performance liquid chromatographic determination of avenanthramides, N-aroylanthranilic acid alkaloids from oats. J. Chromatogr. 45:1988;363-370
27. Dimberg L.H., Theander O., Lingnert H. Avenanthramides - a group of phenolic antioxidants in oats. Cereal Chem. 70:1993;637-641
28. Peterson D.M., Hahn M., Emmons C.L. Oat avenanthramides exhibit antioxidant activities in vitro. Food Chem. 79:2002;473-478
29. Bratt K., Sunnerheim K., Bryngelsson S., et al. Avenanthramides in oats (Avena sativa L.) and structure-antioxidant activity relationships. J. Agric. Food Chem. 51:2003;594-600
30. Emmons C.L., Peterson D.M., Paul G.L. Antioxidant capacity of oat (Avena sativa L.) extracts. 2. In vitro antioxidant activity and contents of phenolic and tocol antioxidants. J. Agric. Food Chem. 47:1999;4894-4898
31. Peterson D.M., Emmons C.L., Hibbs A.H. Phenolic antioxidants and antioxidant activity in pearling fractions of oat groats. J. Cereal Sci. 33:2001;97-103
32. Emmons C.L., Peterson D.M. Antioxidant activity and phenolic content of oat as affected by cultivar and location. Crop Sci. 41:2001;1676-1681
33. Krishnaswamy G., Kelley J., Yerra L., Smith J.K., Chi D.S. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J. Interferon Cytokine Res. 19:1999;91-104
34. DiCorleto P.E., de la Motte C.A. Characterization of the adhesion of the human monocytic cell line U937 to cultured endothelial cells. J. Clin. Invest. 75:1985;1153-1161
35. Vaporciyan A.A., Jones M.L., Ward P.A. Rapid analysis of leukocyte-endothelial adhesion. J. Immunol. Methods. 159:1993;93-100
36. Collins FW, Fielder DA, Starr AB, Redmond MJ, D'Attilio RZ, Process for the isolation, purification and recovery of non-polar extractives. US Patent #6, 495, 140, 2002.
37. Meydani S.N., Meydani M., Blumberg J.B., et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects: a randomized controlled trial. JAMA. 277:1997;1366-1380
38. Yue T.L., McKenna P.J., Gu J.L., Feuerstein G.Z. Interleukin-8 is chemotactic for vascular smooth muscle cells. Eur. J. Pharmacol. 240:1993;81-84
39. Apostolopoulos J., Davenport P., Tipping P.G. Interleukin-8 production by macrophages from atheromatousplaques. Arterioscler. Thromb. Vasc. Biol. 16:1996;1007-1012
40. Nakae H., Endo S., Inada K., Kasai T., Yoshida M. Significance of alpha-tocopherol and interleukin-8 in septic adult respiratory distress syndrome. Res. Commun. Chem. Pathol. Pharmacol. 84:1994;197-202
41. Simonini A., Moscucci M., Muller D.W., et al. IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation. 101:2000;1519-1526
42. Berkhout T.A., Sarau H.M., Moores K., et al. Cloning, in vitro expression, and functional characterization of a novel human CC chemokine of the monocyte chemotactic protein (MCP) family (MCP-4) that binds and signals through the CC chemokine receptor 2B. J. Biol. Chem. 272:1997;16404-16413
43. Cushing S.D., Berliner J.A., Valente A.J., et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A. 87:1990;5134-5138
44. Wilcox J.N., Nelken N.A., Coughlin S.R., Gordon D., Schall T.J. Local expression of inflammatory cytokines in human atherosclerotic plaques. J. Atheroscler. Thromb. 1:1994;S10-S13
45. Nelken N.A., Coughlin S.R., Gordon D., Wilcox J.N. Monocyte chemoattractantprotein-1 in human atheromatousplaques. J. Clin. Invest. 88:1991;1121-1127
46. Yokota T., Hansson G.K. Immunological mechanisms in atherosclerosis. J. Intern. Med. 238:1995;479-489
47. Watson C., Whittaker S., Smith N., et al. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin. Exp. Immunol. 105:1996;112-119
48. Libby P., Hansson G.K. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab. Invest. 64:1991;5-15
49. Basha B.J., Sowers J.R. Atherosclerosis: an update. Am. Heart J. 131:1996;1192-1202
50. Krieglstein C.F., Granger D.N. Adhesion molecules and their role in vascular disease. Am. J. Hypertens. 14:2001;44S-54S
51. Tedgui A., Bernard C. Cytokines, immuno-inflammatory response and atherosclerosis. Eur. Cytokine Netw. 5:1994;263-270
52. Printseva O., Peclo M.M., Gown A.M. Various cell types in human atherosclerotic lesions express ICAM-1. Further immunocytochemical and immunochemical studies employing monoclonal antibody 10F3. Am. J. Pathol. 140:1992;889-896
53. Poston R.N., Haskard D.O., Coucher J.R., Gall N.P., Johnson-Tidey R.R. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am. J. Pathol. 140:1992;665-673
54. Whelan J., Ghersa P., Hooft van Huijsduijnen R., et al. An NF kappa B-like factor is essential but not sufficient for cytokine induction of endothelial leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Nucl. Acids Res. 19:1991;2645-2653
55. Collins T., Read M.A., Neish A.S., et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 9:1995;899-909
56. Christman J.W., Lancaster L.H., Blackwell T.S. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 24:1998;1131-1138
57. Schreck R.K., Alberman K., Baeuerle P.A. Nuclear factor κB: an oxidative stree-response transcription factor of eukaryotic cells. Free Radic. Res. Commun. 17:1992;221-237
58. Van den Berg R., Haenen G.R., van den Berg H., Bast A. Transcription factor NF-kappaB as a potential biomarker for oxidative stress. Br. J. Nutr. 86(Suppl 1):2001;S121-S127
59. Mirochnitchenko O., Inouye M. Effect of overexpression of human Cu, Zn superoxide dismutase in transgenic mice on macrophage functions. J. Immunol. 156:1996;1578-1586
60. Bell S., Goldman V.M., Bistrian B.R., et al. Effect ofbeta-glucan from oats and yeast on serum lipids. Crit. Rev. Food Sci. Nutr. 39:1999;189-202
61. Truswell A.S. Dietary fibre and plasma lipids. Eur. J. Clin. Nutr. 49(Suppl 3):1995;S105-S109
62. Tamai H., Katoh K., Yamaguchi T., et al. The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am. Heart J. 143:2002;506-513
63. Rosanio S., Tocchi M., Patterson C., Runge M.S. Prevention of restenosis after percutaneous coronary interventions: the medical approach. Thromb. Haemost. 82(Suppl 1):1999;164-170
64. Slobodzian D.K., Hsieh J.Y., Bayne W.F. Simultaneous determination of tranilast and metabolites in plasma and urine using high-performance liquid chromatography. J. Chromatogr. 345:1985;345-354
65. Miyazawa K., Kikuchi S., Fukuyama J., Hamano S., Ujiie A. Inhibition of PDGF- and TGF-beta-1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis. 118:1995;213-221
66. Takahashi A., Taniguchi T., Ishikawa Y., Yokoyama M. Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53. Circ. Res. 84:1999;543-550
67. Spiecker M., Lorenz I., Marx N., Darius H. Tranilast inhibits cytokine-induced nuclear factor kappaB activation in vascular endothelial cells. Mol. Pharmacol. 62:2002;856-863
68. Chikaraishi A., Hirahashi J., Takase O., et al. Tranilast inhibits interleukin-1-beta-induced monocyte chemoattractantprotein-1 expression in rat mesangial cells. Eur. J. Pharmacol. 427:2001;151-158